Cargando…

Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients

BACKGROUND: Parkinson’s disease (PD) is associated with enteric nervous system dysfunction and gut microbiota dysbiosis. Short-chain fatty acids (SCFAs), derived from gut microbiota, are supposed to anticipate PD pathogenesis via the pathway of spinal cord and vagal nerve or the circulatory system....

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Gang, Jiang, Zhengli, Pu, Yaling, Chen, Shiyong, Wang, Tingling, Wang, Yajing, Xu, Xiaoping, Wang, Shanshan, Jin, Minya, Yao, Yangyang, Liu, Yang, Ke, Shaofa, Liu, Suzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740341/
https://www.ncbi.nlm.nih.gov/pubmed/34996385
http://dx.doi.org/10.1186/s12883-021-02544-7
_version_ 1784629293065699328
author Wu, Gang
Jiang, Zhengli
Pu, Yaling
Chen, Shiyong
Wang, Tingling
Wang, Yajing
Xu, Xiaoping
Wang, Shanshan
Jin, Minya
Yao, Yangyang
Liu, Yang
Ke, Shaofa
Liu, Suzhi
author_facet Wu, Gang
Jiang, Zhengli
Pu, Yaling
Chen, Shiyong
Wang, Tingling
Wang, Yajing
Xu, Xiaoping
Wang, Shanshan
Jin, Minya
Yao, Yangyang
Liu, Yang
Ke, Shaofa
Liu, Suzhi
author_sort Wu, Gang
collection PubMed
description BACKGROUND: Parkinson’s disease (PD) is associated with enteric nervous system dysfunction and gut microbiota dysbiosis. Short-chain fatty acids (SCFAs), derived from gut microbiota, are supposed to anticipate PD pathogenesis via the pathway of spinal cord and vagal nerve or the circulatory system. However, the serum concentration of SCFAs in PD patients is poorly known. This study aims to investigate the exact level of SCFAs in PD patients and its correlation with Parkinson’s symptoms. METHODS: 50 PD patients and 50 healthy controls were recruited, and their demographic and clinical characteristics were collected. The serum concentration of SCFAs was detected using a gas chromatography-mass spectrometer. SCFAs were compared between PD and control groups. The correlation between serum SCFAs and Parkinson’s symptoms and the potential effects of medications on the serum SCFAs was analyzed. RESULTS: Serum propionic acid, butyric acid and caproic acid were lower, while heptanoic acid was higher in PD patients than in control subjects. However, only the serum level of propionic acid was correlated with Unified Parkinson’s Disease Rating Scale (UPDRs) part III score (R = -0.365, P = 0.009), Mini-mental State Examination (MMSE) score (R = -0.416, P = 0.003), and Hamilton Depression Scale (HAMD) score (R = 0.306, P = 0.03). There was no correlation between other serum SCFAs and motor complications. The use of trihexyphenidyl or tizanidine increased the serum concentration of propionic acid. CONCLUSIONS: Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed to test this hypothesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12883-021-02544-7.
format Online
Article
Text
id pubmed-8740341
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87403412022-01-07 Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients Wu, Gang Jiang, Zhengli Pu, Yaling Chen, Shiyong Wang, Tingling Wang, Yajing Xu, Xiaoping Wang, Shanshan Jin, Minya Yao, Yangyang Liu, Yang Ke, Shaofa Liu, Suzhi BMC Neurol Research BACKGROUND: Parkinson’s disease (PD) is associated with enteric nervous system dysfunction and gut microbiota dysbiosis. Short-chain fatty acids (SCFAs), derived from gut microbiota, are supposed to anticipate PD pathogenesis via the pathway of spinal cord and vagal nerve or the circulatory system. However, the serum concentration of SCFAs in PD patients is poorly known. This study aims to investigate the exact level of SCFAs in PD patients and its correlation with Parkinson’s symptoms. METHODS: 50 PD patients and 50 healthy controls were recruited, and their demographic and clinical characteristics were collected. The serum concentration of SCFAs was detected using a gas chromatography-mass spectrometer. SCFAs were compared between PD and control groups. The correlation between serum SCFAs and Parkinson’s symptoms and the potential effects of medications on the serum SCFAs was analyzed. RESULTS: Serum propionic acid, butyric acid and caproic acid were lower, while heptanoic acid was higher in PD patients than in control subjects. However, only the serum level of propionic acid was correlated with Unified Parkinson’s Disease Rating Scale (UPDRs) part III score (R = -0.365, P = 0.009), Mini-mental State Examination (MMSE) score (R = -0.416, P = 0.003), and Hamilton Depression Scale (HAMD) score (R = 0.306, P = 0.03). There was no correlation between other serum SCFAs and motor complications. The use of trihexyphenidyl or tizanidine increased the serum concentration of propionic acid. CONCLUSIONS: Serum SCFAs are altered in PD patients, and the decrease of serum propionic acid level is correlated with motor symptoms, cognitive ability and non-depressed state. Thus, the gut microbial-derived SCFAs potentially affect Parkinson’s symptoms through the blood circulation. Propionic acid supplementation might ameliorate motor and non-motor symptoms of PD patients, although clinical trials are needed to test this hypothesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12883-021-02544-7. BioMed Central 2022-01-07 /pmc/articles/PMC8740341/ /pubmed/34996385 http://dx.doi.org/10.1186/s12883-021-02544-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wu, Gang
Jiang, Zhengli
Pu, Yaling
Chen, Shiyong
Wang, Tingling
Wang, Yajing
Xu, Xiaoping
Wang, Shanshan
Jin, Minya
Yao, Yangyang
Liu, Yang
Ke, Shaofa
Liu, Suzhi
Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients
title Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients
title_full Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients
title_fullStr Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients
title_full_unstemmed Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients
title_short Serum short-chain fatty acids and its correlation with motor and non-motor symptoms in Parkinson’s disease patients
title_sort serum short-chain fatty acids and its correlation with motor and non-motor symptoms in parkinson’s disease patients
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740341/
https://www.ncbi.nlm.nih.gov/pubmed/34996385
http://dx.doi.org/10.1186/s12883-021-02544-7
work_keys_str_mv AT wugang serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients
AT jiangzhengli serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients
AT puyaling serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients
AT chenshiyong serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients
AT wangtingling serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients
AT wangyajing serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients
AT xuxiaoping serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients
AT wangshanshan serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients
AT jinminya serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients
AT yaoyangyang serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients
AT liuyang serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients
AT keshaofa serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients
AT liusuzhi serumshortchainfattyacidsanditscorrelationwithmotorandnonmotorsymptomsinparkinsonsdiseasepatients